# US 2024/0392041 A1 · Site-Specific Crosslinking of Antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392041 A1
- Document ID: US20240392041A1
- Status: Published application
- Kind: A1
- Application number: 18/772,605
- Filed: 2024-07-15
- Published: 2024-11-28
- Earliest claimed: 2016-06-17
- Assignees: Life Technologies Corporation
- Applicants: Life Technologies Corporation
- Inventors: Brian Agnew; Robert Aggeler; Rolando Brawer
- Web page: https://patentgrep.com/patent/US20240392041A1

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6879: {the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}
- A61K 47/6881: {Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other}
- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12P 21/005: {Glycopeptides, glycoproteins}
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- C12Y 302/01023: Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
- C12Y 302/01096: Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
- G01N 33/6854: {Immunoglobulins}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/31: multispecific
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/54: F(ab')2
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3513: Protein; Peptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods are provided for making bispecific antibodies and antibody conjugates comprising site-specifically cross-linking two or more antibodies, antibody fragments or Fc-fusion proteins. Also provided are compositions and uses for the bispecific antibodies and antibody conjugates. The bispecific antibodies may be used to treat a disease or condition. Also provided are methods for site-specifically conjugating a liposome, an mRNA or an siRNA to an antibody, and uses of the antibody-conjugated liposome, mRNA or siRNA.

## Claims

### Claim 1

A method of making a bispecific antibody or antibody conjugate, the method comprising:
a) providing:
a first antibody fragment comprising a terminal GlcNAc residue, or
a first Fc-fusion protein comprising a terminal GlcNAc residue;
b) contacting the first antibody fragment or first Fc-fusion protein with a modified sugar comprising a chemical handle and a galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes the attachment of the first modified sugar to the terminal GlcNAc residue of the first antibody fragment or first Fc-fusion protein thereby forming a first modified antibody fragment or a first modified Fc-fusion protein;
c) providing a first activating molecule comprising a first crosslinking group, a first reactive group, and optionally a linker;
d) contacting the first modified antibody fragment or first modified Fc-fusion protein with the first activating molecule, wherein the first activating molecule reacts with the first chemical handle of the first modified antibody fragment or first modified Fc fusion protein, thereby forming a first activated antibody fragment or first activated Fc-fusion protein;
e) providing:
a second antibody fragment comprising a terminal GlcNAc residue, or
a second Fc-fusion protein comprising a terminal GlcNAc residue;
f) contacting the second antibody fragment or second Fc-fusion protein with the modified sugar and the galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes attachment of the modified sugar to the terminal GlcNAc residue of the second antibody fragment or second Fc-fusion protein thereby forming a second modified antibody fragment or a second modified Fc-fusion protein;
g) providing a second activating molecule comprising a second crosslinking group, a second reactive group and optionally a linker;
h) contacting the second modified antibody fragment or second modified Fc-fusion protein with the second activating molecule, wherein the second activating molecule reacts with the second chemical handle of the second modified antibody fragment or second modified Fc-fusion protein, thereby forming a second activated antibody fragment or a second activated Fc-fusion protein; and
i) contacting the first activated antibody fragment or first activated Fc-fusion protein with the second activated antibody fragment or second activated Fc-fusion protein, wherein the first crosslinking group of the first activated antibody fragment or first activated Fc-fusion protein reacts with the second crosslinking group of the second activated antibody fragment or second activated Fc-fusion protein, thereby forming the bispecific antibody or antibody conjugate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first antibody fragment or first Fc-fusion protein and the second antibody fragment or second Fc-fusion protein are the same.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first antibody, first antibody fragment or first Fc-fusion protein and the second antibody, second antibody fragment or second Fc-fusion protein are different.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein two or more antibody fragments, and/or Fc-fusion proteins are crosslinked.

### Claim at position 6

6-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the chemical handle of the modified sugar comprises an azide group, an alkyne group, a cycloalkene group, a ketone group, an oxime group or a nitrile oxide group.

### Claim 12 (depends on 1)

The method of claim 1, wherein the modified sugar comprising a chemical handle is UDP-GalNAz, UDP-GalKyne, UDP-Gal-Cyclopropene, UDP-GalKetone, UDP-Gal-Oxime or UDP-Gal-Nitrile oxide.

### Claim 13 (depends on 1)

The method of claim 1, wherein the first reactive group and the second reactive group is each independently selected from a dibenzocyclooctyne, a difluorocyclooctyne, an aza-dibenzocyclooctyne, or a cyclononyne.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the first crosslinking group and the second reactive group is each independently selected from a trans-cyclooctene (TCO), a cyclopropene, or a tetrazine.

### Claim at position 12

16-18. (canceled)

### Claim 19 (depends on 1)

The method of claim 1, further comprising prior to step (a),
providing a first antibody fragment or a first Fc-fusion protein comprising an oligosaccharide having a GlcNAc-GlcNAc linkage; and
contacting the first antibody fragment or first Fc-fusion protein comprising an oligosaccharide having a GlcNAc-GlcNAc linkage with an enzyme that cleaves the oligosaccharide at the GlcNAc-GlcNAc linkage to provide the first antibody fragment comprising a terminal GlcNAc residue or the first Fc-fusion protein comprising a terminal GlcNAc residue.

### Claim 20 (depends on 1)

The method of claim 1, further comprising prior to step (e),
providing a second antibody fragment or second Fc-fusion protein comprising an oligosaccharide having a GlcNAc-GlcNAc linkage; and
contacting the second antibody fragment or second Fc-fusion protein comprising an oligosaccharide having a GlcNAc-GlcNAc linkage with an enzyme that cleaves the oligosaccharide at the GlcNAc-GlcNAc linkage to provide the second antibody fragment comprising a terminal GlcNAc residue, or the second Fc-fusion protein comprising a terminal GlcNAc residue.

### Claim 21 (depends on 19)

The method of claim 19, wherein the enzyme is an endoglycosidase.

### Claim at position 16

22-31. (canceled)

### Claim 32 (depends on 1)

The method of claim 1, wherein the galactosyl transferase enzyme is a mutant galactosyl transferase enzyme.

### Claim at position 18

33-42. (canceled)

### Claim 43 (depends on 1)

The method of claim 1, wherein
(i) steps (a) through (d) are performed before steps (e) through (h);
(ii) steps (a) through (d) are performed after steps (e) through (h); or
(iii) steps (a) through (d) are performed concurrently with steps (e) through (h).

### Claim at position 20

44-51. (canceled)

### Claim 52 (depends on 1)

The method of claim 1, wherein the linker comprises:
a) one or more polyethylene glycol (PEG) groups;
b) 1 to 300 PEG groups;
c) 1 to 250 PEG groups;
d) 1 to 200 PEG groups;
e) 1 to 150 PEG groups;
f) 1 to 100 PEG groups;
g) 1 to 75 PEG groups;
h) 1 to 50 PEG groups;
i) 1 to 40 PEG groups;
j) 1 to 30 PEG groups;
k) 1 to 25 PEG groups;
l) 1 to 20 PEG groups;
m) 1 to 15 PEG groups;
n) 1 to 10 PEG groups;
o) 1 to 5 PEG groups; or
p) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 40, 41, 42, 43, 44, 45 46, 47, 48, 49 or 50 PEG groups.

### Claim at position 22

53-57. (canceled)

### Claim 58 (depends on 1)

A bispecific antibody or antibody conjugate obtained by the method of claim 1.

### Claim at position 24

59-124. (canceled)

### Claim 125 (depends on 139)

A method of treating a disease, disorder or condition in a subject in need thereof comprising administering the bispecific antibody or antibody conjugate of claim 139.

### Claim at position 26

126-130. (canceled)

### Claim 131 (depends on 139)

A method of diagnosing a disease, disorder or condition in a subject, the method comprising:
(a) contacting a sample obtained from a subject suspected of having the disease with the bispecific antibody or antibody conjugate of claim 139 to form a contacted sample;
(b) incubating the contacted sample for an appropriate amount of time to form an incubated sample;
(c) illuminating the incubated sample with an appropriate wavelength to form an illuminated sample; and
(d) detecting fluorescent emissions from the illuminated sample;
wherein the fluorescent emissions are used to diagnose or detect the disease.

### Claim at position 28

132-133. (canceled)

### Claim 134

A method for screening bispecific antibodies and antibody conjugates, the method comprising:
a) providing:
a first antibody comprising a terminal GlcNAc residue,
a first antibody fragment comprising a terminal GlcNAc residue, or
a first Fc-fusion protein comprising a terminal GlcNAc residue;
b) contacting the first antibody, first antibody fragment or first Fc-fusion protein with a modified sugar comprising a chemical handle and a galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes attachment of the modified sugar to the terminal GlcNAc residue of the first antibody, first antibody fragment or first Fc-fusion protein thereby forming a first modified antibody, a first modified antibody fragment or a first modified Fc-fusion protein;
c) providing a first activating molecule comprising a first crosslinking group, a first reactive group, and optionally a linker;
d) contacting the first modified antibody, first modified antibody fragment or first modified Fc-fusion protein with the first activating molecule, wherein the first activating molecule reacts with the first chemical handle of the first modified antibody, first modified antibody fragment or first Fc-fusion protein at the first chemical handle, thereby forming a first activated antibody, first activated antibody fragment or first activated Fc-fusion protein;
e) providing:
a second antibody comprising a terminal GlcNAc residue,
a second antibody fragment comprising a terminal GlcNAc residue, or
a second Fc-fusion protein comprising a terminal GlcNAc residue;
f) contacting the second antibody, second antibody fragment or second Fc-fusion protein with the modified sugar and the galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes attachment of the modified sugar to the terminal GlcNAc residue of the second antibody thereby forming a second modified antibody, a second modified antibody fragment or a second modified Fc-fusion protein;
g) providing a second activating molecule comprising a second crosslinking group, a second reactive group and optionally, a linker;
h) contacting the second modified antibody, second modified antibody fragment or second modified Fc-fusion protein with the second activating molecule, wherein the second activating molecule reacts with the second chemical handle of the second modified antibody, second modified antibody fragment or second modified Fc-fusion protein at the second chemical handle, thereby forming a second activated antibody, a second activated antibody fragment or a second modified Fc-fusion protein;
i) contacting the first activated antibody, first activated antibody fragment or first activated Fc-fusion protein with the second activated antibody, second activated antibody fragment or second activated Fc-fusion protein, wherein the first crosslinking group of the first activated antibody, first activated antibody fragment or first activated Fc-fusion protein reacts with the second crosslinking group of the second activated antibody, second activated antibody fragment or second activated Fc-fusion protein, thereby forming the bispecific antibody or antibody conjugate; and
j) analyzing the bispecific antibodies or antibody conjugates for functionality.

### Claim at position 30

135-138. (canceled)

### Claim 139

A bispecific antibody or antibody conjugate comprising:
a first activated antibody, antibody fragment or Fc-fusion protein comprising a first activating molecule; and
a second activated antibody, antibody fragment or Fc-fusion protein comprising a second activating molecule;
wherein the first activated antibody, antibody fragment or Fc-fusion protein and the second activated antibody, antibody fragment or Fc-fusion protein are crosslinked together via reaction of the first activating molecule and the second activating molecule; and
wherein the first activated antibody, antibody fragment or Fc-fusion protein is crosslinked to the second antibody, antibody conjugate or Fc-fusion protein via a single crosslink.

### Claim 140 (depends on 139)

The bispecific antibody or antibody conjugate of claim 139, wherein the first activating molecule comprises i) a first crosslinking group selected from an alkene and a tetrazine, ii) a first reactive group comprising a cyclooctyne, and iii) optionally a linker, and the second activating molecule comprises i) a first crosslinking group selected from an alkene and a tetrazine, ii) a first reactive group comprising a cyclooctyne, and iii) optionally a linker.
